ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

This study has been terminated.
Study NCT00000330.   Last updated on November 3, 2005.   Information provided by National Institute on Drug Abuse (NIDA)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
Official Title  Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2
Brief Summary

The purpose of this study is to assess the abuse liability and reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in heroin-dependent volunteers

Detailed Description

not available at this time

Study Phase Phase II
Study Type  Interventional
Study Design  Treatment, Double-Blind, Placebo Control
Primary Outcome Measure  Subjective dose estimate
Observed withdrawal rating
Opioid antagonist rating
Pupil diameter
Analog rating scale for drug effects
Drug effect characteristics
Drug/Money Preferences
Secondary Outcome Measure 
Condition  Heroin Dependence
Opioid-Related Disorders
Intervention  Drug: Opioid-Related Disorders
MEDLINE PMIDs
Links
Recruitment Information Fields
Recruitment Status  Terminated
Enrollment  0
Start Date  October 1999
Completion Date
Eligibility Criteria 

Inclusion Criteria:

Individuals must be at least 18 yrs of age, currently opioid dependent and must not be seeking treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.

Exclusion Criteria:

Individuals with evidence of an active DSM-IV Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Gender Both
Ages 18 Years to 65 Years
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00000330
Organization ID NIDA-11160-5
Secondary IDs †† R01-11160-5
Study Sponsor  National Institute on Drug Abuse (NIDA)
Collaborators †† University of Colorado at Denver and Health Sciences Center
Investigators 
Principal Investigator:     Leslie Amass, Ph.D.     University of Colorado at Denver and Health Sciences Center    
Information Provided By National Institute on Drug Abuse (NIDA)
Verification Date October 1999
First Received Date  September 20, 1999
Last Updated Date November 3, 2005

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers